cutting out all the crap -i am not very far from the truth dr.paul sharpe is as i write in the u.s. --obviously promoting minster pharma --this company with its unique and close conection with smith/kline/glaxo imo definately makes this a share to strongly buy for the future --with joint ventures and new drugs to market and almost a fait a compli this share is going to become a stock market darling during the next two years --a reasonable target price at least 30p per share dyor